that is required for submissions to the SRDP and providing a streamlined and
standardized format for the presentation of the required information. Form
Number: CMS–10328 (OMB control number: 0938–1106); Frequency:
Annually and semi-annually; Affected Public: Private sector (Business or other
for-profits and Not-for-profits); Number of Respondents: 200; Total Annual
Responses: 200; Total Annual Hours: 5,000. (For policy questions regarding
this collection contact Matt Edgar at 410–786–0698.)


William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.

[FR Doc. 2016–10705 Filed 5–5–16; 8:45 am]
BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2013–N–1687]

Advisory Committee; Pharmacy
Compounding Advisory Committee,
Renewal

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice; renewal of advisory
committee.

SUMMARY: The Food and Drug
Administration (FDA) is announcing the
renewal of the Pharmacy Compounding
Advisory Committee established to provide advice to the
Commissioner. The Pharmacy Compounding Advisory Committee
advises the Commissioner or designee in
discharging responsibilities as they
relate to compounded drugs for human
use and, as required, any other product for
which the Food and Drug
Administration has regulatory
responsibility.

The Committee shall provide advice
on scientific, technical, and medical
issues concerning drug compounding
under sections 503A and 503B of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 353a) and (21 U.S.C. 353b),
and, as required, any other product for
which the Food and Drug
Administration has regulatory
responsibility, and make appropriate
recommendations to the Commissioner of Food and Drugs.

The Committee shall consist of a core
of 12 voting members including the
Chair. Members and the Chair are
selected by the Commissioner or
designee from among authorities
knowledgeable in the fields of
pharmaceutical compounding,
pharmaceutical manufacturing,
pharmacy, medicine, and related
specialties. These members will include
representatives from the National
Association of Boards of Pharmacy, the
United States Pharmacopeia,
pharmacists with current experience
and expertise in compounding,
physicians with background and
knowledge in compounding, and patient
and public health advocacy
organizations. Members will be invited
to serve for overlapping terms of up to
4 years. Almost all non-Federal
members of this committee serve as
Special Government Employees. The
core of voting members may include one
or more technically qualified members,
selected by the Commissioner or
designee, who are identified with
consumer interests and are
recommended by either a consortium of
consumer-oriented organizations or
other interested persons. In addition to
the voting members, the Committee may
include one or more non-voting
members who are identified with
industry interests.

Further information regarding the
most recent charter and other
information can be found at http://
www.fda.gov/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/
PharmacyCompoundingAdvisory
Committees/default.htm or by
contacting the Designated Federal
Officer (see FOR FURTHER
INFORMATION CONTACT).

In light of the fact that no
change has been made to the committee
name or description of duties, no
amendment will be made to 21 CFR
14.100.

This document is issued under the
Federal Advisory Committee Act (5
U.S.C. app.). For general information
related to FDA advisory committees,
please visit us at http://www.fda.gov/
AdvisoryCommittees/default.htm.


Jill Hartzler Warner,
Associate Commissioner for Special Medical
Programs.

[FR Doc. 2016–10585 Filed 5–5–16; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Health Resources and Services
Administration

Agency Information Collection
Activities: Proposed Collection: Public
Comment Request

AGENCY: Health Resources and Services
Administration, HHS.

ACTION: Notice.

SUMMARY: In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects (section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995), the
Health Resources and Services
Administration (HRSA) announces
plans to submit an Information
Collection Request (ICR), described
below, to the Office of Management and
Budget (OMB). Prior to submitting the
ICR to OMB, HRSA seeks comments
from the public regarding the burden
estimate, below, or any other aspect of
the ICR.

DATES: Comments on this Information
Collection Request must be received no
later than July 5, 2016.

ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 14N–39, Parklawn
Building, 5600 Fishers Lane, Rockville,
MD 20857.

FOR FURTHER INFORMATION
CONTACT: To request more information on
the proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call the HRSA Information Collection
Clearance Officer at (301) 443–1984.

SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference.